CN121263199A - 用于治疗癌症的与braf抑制剂的组合疗法 - Google Patents

用于治疗癌症的与braf抑制剂的组合疗法

Info

Publication number
CN121263199A
CN121263199A CN202480037690.XA CN202480037690A CN121263199A CN 121263199 A CN121263199 A CN 121263199A CN 202480037690 A CN202480037690 A CN 202480037690A CN 121263199 A CN121263199 A CN 121263199A
Authority
CN
China
Prior art keywords
cancer
seq
combination
polypeptide
braf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202480037690.XA
Other languages
English (en)
Chinese (zh)
Inventor
马里亚诺·费德里科·扎卡里亚斯·弗洛克
雅斯特林简·考尔
劳拉·苏切克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Original Assignee
Institucio Catalana de Recerca i Estudis Avancats ICREA
Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institucio Catalana de Recerca i Estudis Avancats ICREA, Fundacio Privada Institut dInvestigacio Oncologica Vall dHebron filed Critical Institucio Catalana de Recerca i Estudis Avancats ICREA
Publication of CN121263199A publication Critical patent/CN121263199A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202480037690.XA 2023-06-07 2024-06-06 用于治疗癌症的与braf抑制剂的组合疗法 Pending CN121263199A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23382554 2023-06-07
EP23382554.6 2023-06-07
PCT/EP2024/065545 WO2024251854A1 (en) 2023-06-07 2024-06-06 Combination therapy with braf inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN121263199A true CN121263199A (zh) 2026-01-02

Family

ID=86732645

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202480037690.XA Pending CN121263199A (zh) 2023-06-07 2024-06-06 用于治疗癌症的与braf抑制剂的组合疗法

Country Status (7)

Country Link
EP (1) EP4724083A1 (de)
KR (1) KR20260020418A (de)
CN (1) CN121263199A (de)
AU (1) AU2024285758A1 (de)
IL (1) IL325025A (de)
TW (1) TW202502371A (de)
WO (1) WO2024251854A1 (de)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE3169595D1 (en) 1980-11-10 1985-05-02 Gersonde Klaus Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
EP0786522A2 (de) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6447796B1 (en) 1994-05-16 2002-09-10 The United States Of America As Represented By The Secretary Of The Army Sustained release hydrophobic bioactive PLGA microspheres
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
DE69941447D1 (de) 1998-01-05 2009-11-05 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
AU767394C (en) 1999-12-29 2005-04-21 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
US20020130430A1 (en) 2000-12-29 2002-09-19 Castor Trevor Percival Methods for making polymer microspheres/nanospheres and encapsulating therapeutic proteins and other products
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
US7060498B1 (en) 2001-11-28 2006-06-13 Genta Salus Llc Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
US7141540B2 (en) 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
SG187991A1 (en) 2002-05-02 2013-03-28 Wyeth Corp Calicheamicin derivative-carrier conjugates
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
ATE496944T1 (de) 2003-07-21 2011-02-15 Immunogen Inc Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
DK3248613T3 (da) 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
MX2010005603A (es) 2007-11-26 2010-08-02 Bayer Schering Pharma Ag Anticuerpos antimesotelina y usos de los mismos.
WO2009080832A1 (en) 2007-12-26 2009-07-02 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
US9120854B2 (en) 2008-04-11 2015-09-01 Seattle Genetics, Inc. Detection and treatment of pancreatic, ovarian and other cancers
BR112013007160A2 (pt) 2010-09-29 2016-06-14 Philogen Spa ligante tiazolidina para a conjugação de fármacos a anticorpos
PE20141937A1 (es) 2011-11-16 2014-12-18 Amgen Inc Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
EP2988786A4 (de) 2013-04-22 2016-12-21 Avelas Biosciences Inc Zusammensetzungen für selektive arzneiverabreichung und verfahren zur verwendung
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10550190B2 (en) 2014-04-04 2020-02-04 Merck Sharp & Dohme Corp. Phosphate based linkers for intracellular delivery of drug conjugates
WO2015183883A1 (en) * 2014-05-29 2015-12-03 Memorial Sloan Kettering Cancer Center Systems and methods for identifying drug combinations for reduced drug resistance in cancer treatment
KR102508023B1 (ko) 2014-09-03 2023-03-10 이뮤노젠 아이엔씨 세포-결합제 및 세포독성 약물을 포함하는 콘주게이트
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
WO2019018898A1 (en) 2017-07-28 2019-01-31 Phylogica Limited CELL PENETRATING PEPTIDES AND RELATED COMPOSITIONS AND METHODS
US20200164034A1 (en) * 2018-10-24 2020-05-28 Board Of Regents, The University Of Texas System Methods for improving sex-dimorphic responses to targeted therapy in melanoma
CN113795264A (zh) * 2019-03-19 2021-12-14 瓦尔希伯伦私人肿瘤研究基金会 采用Omomyc和结合PD-1或CTLA-4的抗体治疗癌症的联合疗法

Also Published As

Publication number Publication date
IL325025A (en) 2026-01-01
EP4724083A1 (de) 2026-04-15
WO2024251854A1 (en) 2024-12-12
TW202502371A (zh) 2025-01-16
AU2024285758A9 (en) 2026-01-15
KR20260020418A (ko) 2026-02-11
AU2024285758A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
AU2020242284B2 (en) Combination therapy for the treatment of cancer
US20160166637A1 (en) Methods of treating a cancer through targeted disruption of alpha connexin 43-zonula occludens-1 (zo-1) interaction
CN121263199A (zh) 用于治疗癌症的与braf抑制剂的组合疗法
TWI908116B (zh) 用於治療癌症的與ｋｒａｓ抑制劑的組合療法
CN121335714A (zh) 用于治疗癌症的与mek抑制剂的组合疗法
US11566247B2 (en) Modulation of alternative MDM2 splicing
CN120166937A (zh) 用于治疗癌症的联合疗法
WO2007109908A1 (en) Therapeutic yb-1 phosphorylation decoys
TW202602916A (zh) 用於治療自體免疫性疾病的化合物及其應用
EA046326B1 (ru) Комбинированная терапия для лечения рака
JP2020147555A (ja) 抗がん剤抵抗性改善作用を有するクローディン−２結合性短鎖ペプチドの開発
HK1173184A (en) Sparc antisense compositions and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication